ストックスクリーナーアプリを入手
3.44
2.69%
0.09
前日終値:
$3.35
開ける：
$3.38
24時間の取引高:
1.61M
Relative Volume:
0.92
時価総額：
$366.94M
収益：
当期純損益:
$-58.88M
株価収益率:
-3.0924
EPS:
-1.1124
ネットキャッシュフロー:
$-42.79M
1週間 パフォーマンス:
+4.56%
1か月 パフォーマンス:
-7.77%
6か月 パフォーマンス:
-53.32%
1年 パフォーマンス:
+40.41%
1日の値動き範囲:
$3.29
$3.485
1週間の範囲:
$3.175
$3.485
52週間の値動き範囲:
$2.15
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RLMD
Relmada Therapeutics Inc
|
3.44 | 366.94M | 0 | -58.88M | -42.79M | -1.1124 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-18 | 開始されました | H.C. Wainwright | Buy |
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
| 2026-01-23 | 再開されました | Leerink Partners | Outperform |
| 2025-12-22 | 開始されました | Jefferies | Buy |
| 2025-11-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics Inc Statistics – HAN:4E2 - TradingView
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement - Seeking Alpha
Top insider buys and sells disclosed on Friday - Investing.com
Top insider buys and sells disclosed on Friday By Investing.com - Investing.com UK
RLMD Jumps As Executives Buy Shares And Signal Confidence - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Interest - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus - timothysykes.com
RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus - timothysykes.com
Relmada Therapeutics (RLMD) CFO Maged Shenouda Buys 200,000 Shar - GuruFocus
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Nigeria
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 - Investing.com India
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - Investing.com
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares By Investing.com - Investing.com India
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Canada
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares By Investing.com - Investing.com UK
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com UK
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - investing.com
Relmada Therapeutics Insiders Purchased Shares Worth Over $1.6M - TradingView
Relmada (NASDAQ: RLMD) CEO buys stock in two open-market trades - Stock Titan
Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market - Stock Titan
Relmada Therapeutics CEO Sergio Traversa Acquires 200,000 Shares in Two-Day Open Market Transactions - Kalkine Media
Relmada Therapeutics CEO Sergio Traversa Acquires 200,000 Shares at $4.10-$4.18 (NASDAQ: RLMD) - Kalkine Media
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 - Investing.com
Relmada Therapeutics (NASDAQ: RLMD) Announces Departure of CMO Dr. Raj S. Pruthi Effective September 3, 2026 - Kalkine Media
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - stocktitan.net
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighMcClellan Oscillator - dars.gov.et
Relmada Therapeutics Inc. (RLMD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Relmada Therapeutics Inc. (RLMD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Relmada Therapeutics (RLMD) Slips 0.87% as Shares Defend Support at $4.32Put Call Ratio - dars.gov.et
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Relmada (RLMD) Chart: Moves 0.54% Down to $4.61 in the Latest Session; Levels: Price Remains Between $4.38 Support and $4.84 Resistance on the DayIchimoku Entry - siam.in
Relmada (RLMD) Results Breakdown: The Bottom-Line Figure Beats Its Comparison on the Day; Share Response: Shares Move Lower 0.22% in the Latest ReadingCost Structure Review - vinanet.vn
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com Nigeria
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com South Africa
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
Relmada Therapeutics Inc (RLMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Sep 10 '26 |
Buy |
4.25 |
79,800 |
339,150 |
1,000,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '26 |
Buy |
4.10 |
100,000 |
410,000 |
1,500,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '26 |
Buy |
4.18 |
100,000 |
418,000 |
1,400,000 |
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| TRAVERSA SERGIO | Chief Executive Officer |
Dec 15 '25 |
Buy |
4.12 |
27,500 |
113,300 |
1,300,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
2.14%
大文字化:
|
ボリューム (24 時間):